keyword
MENU ▼
Read by QxMD icon Read
search

Esomeprazole

keyword
https://www.readbyqxmd.com/read/28102361/effectiveness-and-tolerability-of-different-recommended-doses-of-ppis-and-h2ras-in-gerd-network-meta-analysis-and-grade-system
#1
Chao Zhang, Joey S W Kwong, Rui-Xia Yuan, Hao Chen, Chang Xu, Yi-Pin Wang, Gong-Li Yang, Jin-Zhu Yan, Le Peng, Xian-Tao Zeng, Hong Weng, Jie Luo, Yu-Ming Niu
Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro-esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs, H2RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome...
January 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28094314/reassessment-of-rebleeding-risk-of-forrest-ib-oozing-peptic-ulcer-bleeding-in-a-large-international-randomized-trial
#2
Dennis M Jensen, Stefan Eklund, Tore Persson, Henrik Ahlbom, Robert Stuart, Alan N Barkun, Ernest J Kuipers, Joachim Mössner, James Y Lau, Joseph J Sung, Jan Kilhamn, Tore Lind
OBJECTIVES: Our aims were to assess risks of early rebleeding after successful endoscopic hemostasis for Forrest oozing (FIB) peptic ulcer bleeding (PUBs) compared with other stigmata of recent hemorrhage (SRH). METHODS: These were post hoc multivariable analyses of a large, international, double-blind study (NCT00251979) of patients randomized to high-dose intravenous (IV) esomeprazole (PPI) or placebo for 72 h. Rebleeding rates of patients with PUB SRH treated with either PPI or placebo after successful endoscopic hemostasis were also compared...
January 17, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28070941/the-effect-of-baseline-characteristics-on-the-response-to-proton-pump-inhibitors-in-patients-with-peptic-ulcer-bleeding
#3
James Lau, Tore Lind, Tore Persson, Stefan Eklund
BACKGROUND: The rate of rebleeding from peptic ulcers could differ between Asian and Western populations. AIM: To determine whether the observed twofold difference in rebleeding rates in two similarly designed clinical trials (one in Hong Kong [n=240], the other in a multinational Western population [n=764, http://ClinicalTrials.gov Identifier: NCT00251979]) can be explained by differences in baseline patient characteristics. METHODS: Two-factor and multifactor analyses (adjusted by demographics, established risk factors for peptic ulcer and peptic ulcer bleeding, and disease severity variables) were performed using pooled data from the two studies...
January 10, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28052855/syn-004-ribaxamase-an-oral-%C3%AE-lactamase-designed-to-protect-the-gut-microbiome-from-the-deleterious-effects-of-certain-intravenously-administered-%C3%AE-lactam-antibiotics-degrades-ceftriaxone-excreted-into-the-intestine-in-phase-2a-clinical-studies
#4
John F Kokai-Kun, Tracey Roberts, Olivia Coughlin, Eric Sicard, Marianne Rufiange, Richard Fedorak, Christian Carter, Marijke H Adams, James Longstreth, Heidi Whalen, Joseph Sliman
SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action is to degrade excess β-lactam antibiotic that is excreted into the small intestine. This enzymatic inactivation of excreted antibiotic is expected to protect the gut microbiome from disruption and thus prevent undesirable side effects including secondary infections like Clostridium difficile as well as other antibiotic-associated diarrheas...
January 4, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28030862/a-comparative-study-of-a-new-class-of-gastric-acid-suppressant-agent-named-vonoparazan-versus-esomeprazole-for-the-eradication-of-helicobacter-pylori
#5
Masahiro Tsujimae, Hiroshi Yamashita, Hiroki Hashimura, Chise Kano, Keiko Shimoyama, Atsushi Kanamori, Kei Matsumoto, Akio Koizumi, Kenji Momose, Takaaki Eguchi, Takumi Fukuchi, Mikio Fujita, Akihiko Okada
BACKGROUND: Helicobacter pylori eradication rates have decreased worldwide. Gastric acid inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial. OBJECTIVE: To determine the efficacy of VPZ for H. pylori eradication. METHODS: A total of 874 patients were enrolled; 431 received esomeprazole (EPZ) and 443 received VPZ...
2016: Digestion
https://www.readbyqxmd.com/read/28008288/a-case-of-probable-esomeprazole-induced-transient-liver-injury-in-a-pregnant-woman-with-hyperemesis
#6
Binny Thomas, Mahmoud Mohamed, Moza Al Hail, Fatma Alzahra Y Awwad, Ramy M Wahba, Sabir B Hassan, Khalid Omar, Wessam El Kassem, Palivalappila Abdul Rouf
We report a case of 22-year-old primigravida presented to Women's Hospital - Hamad Medical Corporation emergency with severe epigastric pain, nausea, and vomiting. On admission, she was dehydrated with remarkably worsening symptoms. Laboratory findings revealed significantly elevated liver enzymes with unknown etiology. Her past medical history showed an admission for nausea and vomiting 3 weeks previously and she was discharged on antiemetics, and esomeprazole for the first time. Due to the predominantly elevated liver enzymes, the clinical pharmacist discussed the possibility of esomeprazole-induced adverse effects and suggested to suspend esomeprazole based on the evidence from literature review...
2016: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/28007722/physical-compatibility-of-isavuconazonium-sulfate-with-select-i-v-drugs-during-simulated-y-site-administration
#7
Wonhee So, Liz Kim, Abrar K Thabit, David P Nicolau, Joseph L Kuti
PURPOSE: The physical compatibility of isavuconazonium sulfate with 95 i.v. drugs during simulated Y-site administration was studied. METHODS: Isavuconazonium sulfate for injection and all other drugs were reconstituted according to the manufacturer's recommendation and further diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration (1.5 mg/mL for isavuconazonium sulfate and standard concentrations used clinically for other drugs)...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27991853/influences-of-proton-pump-inhibitor-on-helicobacter-pylori-adherence-to-the-gastrointestinal-cell-lines
#8
Marhanis Salihah Omar, Noor Safwah Damanhuri, Endang Kumolosasi
BACKGROUND/AIMS: Helicobacter pylori is a carcinogenic bacterium that could induce P-glycoprotein expression in the human gastrointestinal tract. Bacterial adherence to the gastrointestinal cell lines could be influenced by the level of P-glycoprotein. This study aimed to determine the influence of proton pump inhibitors that exhibit an inhibitory effect on P-glycoprotein in gastrointestinal carcinoma cell lines, namely Caco-2 and LS174T, in relation to H. pylori adherence. MATERIALS AND METHODS: Caco-2 and LS174T cells lines treated with omeprazole and esomeprazole were used in this study to assess the bacterial attachment of H...
December 19, 2016: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/27991432/the-effect-of-proton-pump-inhibitors-on-the-cyp2c19-enzyme-activity-evaluated-by-the-pantoprazole-13-c-breath-test-in-gerd-patients-clinical-relevance-for-personalized-medicine
#9
Anil S Modak, Iryna Klyarytska, Valerij Kriviy, Tatjana Tsapyak, Yliya Rabotyagova
Patients with gastroesophageal reflux disease (GERD) are routinely prescribed one of the six FDA approved proton pump inhibitors (PPI). All of these PPI are inhibitors of CYP2C19 enzyme to varying degrees. The phenotype pantoprazole-(13)C breath test (Ptz-BT) was used to identify patients who are poor metabolizers (PM) and the extent of phenoconversion of CYP2C19 enzyme activity caused by four PPI (omeprazole, esomprazole pantoprazole and rabeprazole) in 54 newly diagnosed GERD patients prior to initiating randomly selected PPI therapy and 30 d after PPI therapy...
December 17, 2016: Journal of Breath Research
https://www.readbyqxmd.com/read/27988924/successful-eradication-therapy-for-helicobacter-pylori-positive-atrophic-gastritis-at-the-sixth-attempt-a-case-report
#10
Ryuzo Deguchi, Koichi Shiraishi, Yoshitaka Arase, Makiko Dekiden, Hideo Shimada, Hiroshi Miyakita, Takashi Ogimi, Kazunori Myojin, Tetsuya Mine
A 74-year-old woman undergoing outpatient follow-up for reflux esophagitis and atrophic gastritis tested positive for Helicobacter pylori and underwent primary eradication therapy with lansoprazole (LPZ) 30 mg, amoxicillin (AMPC) 750 mg, and clarithromycin (CAM) 200 mg twice daily for 1 week in August 2012. A urea breath test (UBT) after this treatment revealed that eradication had failed. Secondary eradication therapy was carried out with esomeprazole (EPZ) 20 mg, AMPC 750 mg, and metronidazole (MNZ) 250 mg twice daily for 1 week, but this also failed...
December 20, 2016: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/27981489/influence-of-low-dose-proton-pump-inhibitors-administered-concomitantly-or-separately-on-the-anti-platelet-function-of-clopidogrel
#11
Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Mihoko Yamade, Takahiro Uotani, Shu Sahara, Hitomi Ichikawa, Takuma Kagami, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura
Proton pump inhibitors (PPIs) at low doses can effectively prevent gastrointestinal bleeding due to aspirin and are widely used in Japan for gastroprotection in patients taking anti-platelet agents. We examined the influence of different PPIs at low doses administered concomitantly or separately on anti-platelet functions of clopidogrel. In 41 healthy Japanese volunteers with different CYP2C19 genotypes who took clopidogrel 75 mg in the morning alone, or with omeprazole 10 mg, esomeprazole 10 mg, lansoprazole 15 mg, or rabeprazole 10 mg, either concomitantly in the morning or separately in the evening, we measured the inhibition of platelet aggregation (IPA, %) using VerifyNow P2Y12 assay at 4 h after the last clopidogrel dose on Day 7 of each regimen...
December 15, 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/27932981/proton-pump-inhibitors-display-antitumor-effects-in-barrett-s-adenocarcinoma-cells
#12
Eduardo Chueca, Nadezda Apostolova, Juan V Esplugues, María A García-González, Ángel Lanas, Elena Piazuelo
Recent evidence has reported that proton pump inhibitors (PPIs) can exert antineoplastic effects through the disruption of pH homeostasis by inhibiting vacuolar ATPase (H(+)-VATPase), a proton pump overexpressed in several tumor cells, but this aspect has not been deeply investigated in EAC yet. In the present study, the expression of H(+)-VATPase was assessed through the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's esophagus (BE) and the antineoplastic effects of PPIs and cellular mechanisms involved were evaluated in vitro...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27928455/effects-of-esomeprazole-on-the-healing-process-of-post-endoscopic-submucosal-dissection-gastric-ulcers-a-single-arm-prospective-trial
#13
Takashi Ichida, Fumihiko Kusano, Yoshinori Sakai
Objectives: Gastric endoscopic submucosal dissection (ESD) is currently a standard procedure. ESD enables en-bloc resection of large lesions, while inducing larger artificial ulcers to a greater extent than conventional procedures. Several studies have reported that proton pump inhibitors (PPIs) prevent delayed bleeding and expedite the artificial ulcer healing process. Esomeprazole, an S-isomer of omeprazole, is reportedly one of strongest inhibitors of gastric acid secretion. Previous studies have examined the effectiveness of esomeprazole...
2016: Journal of Rural Medicine: JRM
https://www.readbyqxmd.com/read/27918744/efficacy-of-naproxen-with-or-without-esomeprazole-for-pain-and-inflammation-in-patients-after-bilateral-third-molar-extractions-a-double-blinded-crossover-study
#14
G-M Weckwerth, L-F Simoneti, P Zupelari-Gonçalves, A-M Calvo, D-T Brozoski, T-J Dionísio, E-A Torres, J-R-P Lauris, F-A-C Faria, C-F Santos
BACKGROUND: Using a double-blinded randomized crossover design, this study aimed to evaluate acute postoperative pain management, swelling and trismus in 46 volunteers undergoing extractions of the two lower third molars, in similar positions, at two different appointments who consumed a tablet of either NE (naproxen 500 mg + esomepraz ole 20 mg) or only naproxen (500 mg) every 12 hours for 4 days. MATERIAL AND METHODS: Parameters were analyzed: self-reported pain intensity using a visual analog scale (VAS) pre- and postoperative mouth opening; incidence, type and severity of adverse reactions; total quantity consumed of rescue medication; and pre- and postoperative swelling...
January 1, 2017: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/27916213/gastric-ph-and-therapeutic-responses-to-exsomeprazole-in-patients-with-functional-dyspepsia-potential-clinical-implications
#15
Marek Majewski, Irene Sarosiek, Chad J Cooper, Grzegorz Wallner, Richard W McCallum, Stanley A Edlavitch, Jerzy Sarosiek
BACKGROUND: Therapy for functional dyspepsia remains a challenge. This study aimed to evaluate esomeprazole (E) versus placebo (P) regarding (1) the effectiveness in providing relief of abdominal pain or discomfort during 16 weeks of therapy in patients with functional dyspepsia having moderate or severe symptoms; (2) the effects on gastric acid suppression and (3) the relationship between symptom relief and gastric pH. METHODS: Enrolled patients were randomized to E (n = 38) or P (n = 35) in a double-blind, placebo-controlled trial...
December 2016: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/27875488/esomeprazole-fda-approval-in-children-with-gerd-exposure-matching-and-exposure-response
#16
Justin C Earp, Nitin Mehrotra, Kristina E Peters, Robert P Fiorentino, Donna Griebel, Sue Chih Lee, Andrew Mulberg, Kerstin Röhss, Marie Sandström, Amy Taylor, Christoffer W Tornøe, Erica L Wynn, Jan-Stefan Van der Walt, Christine Garnett
OBJECTIVES: FDA approval of proton-pump inhibitors for infantile GERD has been limited by intra-patient variability in the clinical assessment of GERD. For children 1-17 years old, extrapolating efficacy from adults for IV esomeprazole was accepted. The oral formulation was previously approved in children. Exposure-response and exposure matching analyses were sought to identify approvable pediatric doses. METHODS: Intragastric pH biomarker comparisons between children and adults were conducted...
November 19, 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27862093/bioanalytical-method-for-the-estimation-of-co-administered-esomeprazole-leflunomide-and-ibuprofen-in-human-plasma-and-in-pharmaceutical-dosage-forms-using-micellar-liquid-chromatography
#17
Wael Talaat
The present study represents a connection between basic science and clinical applied science through providing a bioanalytical method for the analysis of certain co-administered drugs used for the treatment of rheumatoid arthritis. The studied drugs are esomeprazole, leflunomide and ibuprofen. The proposed bioanalytical method is a simple reversed phase high performance liquid chromatographic method using micellar mobile phase. The method is conducted using a Shim-pack VP-ODS (150 mm × 4.6 mm ID) stainless steel column at ambient temperature with ultraviolet detection at 285 nm...
October 13, 2016: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/27802417/blood-pressure-lowering-effect-of-orally-ingested-nitrite-is-abolished-by-a-proton-pump-inhibitor
#18
Marcelo F Montenegro, Michaela L Sundqvist, Filip J Larsen, Zhengbing Zhuge, Mattias Carlström, Eddie Weitzberg, Jon O Lundberg
Inorganic nitrate and nitrite from dietary and endogenous sources are metabolized to NO and other bioactive nitrogen oxides that affect blood pressure. The mechanisms for nitrite bioactivation are unclear, but recent studies in rodents suggest that gastric acidity may influence the systemic effects of this anion. In a randomized, double-blind, placebo-controlled crossover study, we tested the effects of a proton pump inhibitor on the acute cardiovascular effects of nitrite. Fifteen healthy nonsmoking, normotensive subjects, aged 19 to 39 years, were pretreated with placebo or esomeprazole (3×40 mg) before ingesting sodium nitrite (0...
January 2017: Hypertension
https://www.readbyqxmd.com/read/27801778/antiviral-screening-of-multiple-compounds-against-ebola-virus
#19
Stuart D Dowall, Kevin Bewley, Robert J Watson, Seshadri S Vasan, Chandradhish Ghosh, Mohini M Konai, Gro Gausdal, James B Lorens, Jason Long, Wendy Barclay, Isabel Garcia-Dorival, Julian Hiscox, Andrew Bosworth, Irene Taylor, Linda Easterbrook, James Pitman, Sian Summers, Jenny Chan-Pensley, Simon Funnell, Julia Vipond, Sue Charlton, Jayanta Haldar, Roger Hewson, Miles W Carroll
In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures. A range of compounds currently available with broad antimicrobial activity have been tested for activity against EBOV. Using live EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests...
October 27, 2016: Viruses
https://www.readbyqxmd.com/read/27796466/randomised-trial-of-the-effect-of-a-gastrin-cck2-receptor-antagonist-on-esomeprazole-induced-hypergastrinaemia-evidence-against-rebound-hyperacidity
#20
Malcolm Boyce, Frans van den Berg, Toni Mitchell, Kate Darwin, Steve Warrington
PURPOSE: Hypergastrinaemia induced by proton pump inhibitor (PPI) therapy may cause ECL-cell and parietal-cell hyperplasia and rebound hyperacidity and dyspepsia after PPI withdrawal. The aim of the study was to assess the effect of different dosage-regimens of netazepide, a gastrin/CCK2 receptor antagonist, on PPI-induced hypergastrinaemia and elevated chromogranin A (CgA). METHODS: Six groups of eight healthy subjects participated in a randomised, double-blind study of esomeprazole 40 mg daily for 28 days, in combination with netazepide 1, 5 or 25 mg or placebo, daily, during the last 14 days of esomeprazole or during 14 days after treatment withdrawal...
October 29, 2016: European Journal of Clinical Pharmacology
keyword
keyword
3616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"